[go: up one dir, main page]

MX2017006799A - Formulaciones de complejo de metal. - Google Patents

Formulaciones de complejo de metal.

Info

Publication number
MX2017006799A
MX2017006799A MX2017006799A MX2017006799A MX2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A MX 2017006799 A MX2017006799 A MX 2017006799A
Authority
MX
Mexico
Prior art keywords
chelator
solid phase
excess
metal complex
lanthanide
Prior art date
Application number
MX2017006799A
Other languages
English (en)
Other versions
MX381348B (es
Inventor
Richard Meijer Andreas
Jacob THANING Mikkel
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of MX2017006799A publication Critical patent/MX2017006799A/es
Publication of MX381348B publication Critical patent/MX381348B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La presente invención se refiere a un método de preparación de formulaciones de complejos de metal de lantánido de quelantes macrocíclicos, las cuales comprenden un pequeño exceso de quelante libre. El método usa un quelante depurador unido a fase sólida para remover exceso de iones de metal de lantánido, antes de la adición de un quelante de exceso definido. También se proporciona un método para preparación de agentes de contraste de MRI, junto con sales de meglumina de quelante unido a fase sólida útiles en los métodos. (ver Grafica).
MX2017006799A 2014-11-28 2015-11-27 Método de preparación de una formulación farmacéutica líquida con agente de contraste. MX381348B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1421161.9A GB201421161D0 (en) 2014-11-28 2014-11-28 Metal complex formulations
PCT/EP2015/077958 WO2016083597A1 (en) 2014-11-28 2015-11-27 Metal complex formulations

Publications (2)

Publication Number Publication Date
MX2017006799A true MX2017006799A (es) 2017-09-08
MX381348B MX381348B (es) 2025-03-12

Family

ID=52349616

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006799A MX381348B (es) 2014-11-28 2015-11-27 Método de preparación de una formulación farmacéutica líquida con agente de contraste.

Country Status (12)

Country Link
US (1) US11186553B2 (es)
EP (1) EP3223862A1 (es)
JP (1) JP6709216B2 (es)
KR (1) KR102456908B1 (es)
CN (2) CN118141955A (es)
AU (1) AU2015352418B2 (es)
BR (1) BR112017010867B1 (es)
CA (1) CA2967873C (es)
GB (1) GB201421161D0 (es)
MX (1) MX381348B (es)
RU (1) RU2710360C2 (es)
WO (1) WO2016083597A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201421161D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations
WO2018069176A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2018069179A1 (en) 2016-10-12 2018-04-19 T2Pharma Gmbh Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates
WO2019020662A1 (de) * 2017-07-27 2019-01-31 Sanochemia Pharmazeutika Ag Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen
AT521001B1 (de) * 2018-02-23 2020-10-15 Sanochemia Pharmazeutika Ag Herstellungsverfahren für ein Kontrastmittel
CA3098492A1 (en) * 2018-04-27 2019-12-19 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures
CN108940221A (zh) * 2018-07-27 2018-12-07 福建省微生物研究所 壳聚糖磁性吸附剂除去钆塞酸二钠注射液中游离钆的方法
CN110286168B (zh) * 2019-07-03 2023-03-03 浙江普利药业有限公司 显影剂中多氨基多羧基化合物的测定方法
CN114829346B (zh) * 2019-12-20 2025-06-20 基础核研究和咨询集团 使用基于doat的螯合剂色谱分离金属
GB201919073D0 (en) 2019-12-20 2020-02-05 Ge Healthcare As Novel manufacturing process
EP4284443A4 (en) * 2021-02-01 2025-01-22 Inventure, LLC SYNTHESIS PROCESSES AND COMPOSITIONS WITH LOW INTERMEDIATE AND LOW DICHELATE INTERMEDIATE CONTRAST AGENTS
CN113801071B (zh) * 2021-09-14 2023-04-07 安徽普利药业有限公司 一种钆特酸葡甲胺的精制方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3752062T2 (de) * 1986-12-17 1997-09-11 Glaxo Group Ltd Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008144728A1 (en) * 2007-05-21 2008-11-27 Bracco Imaging S.P.A. Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications
FR2921271A1 (fr) * 2007-09-20 2009-03-27 Guerbet Sa Formulation d'agents de contraste pour l'irm contenant une polybase organique
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
FR2945448B1 (fr) * 2009-05-13 2012-08-31 Guerbet Sa Procede de preparation d'une formulation pharmaceutique de chelate de lanthanide sous forme de poudre.
EP2338874A1 (en) * 2009-12-16 2011-06-29 Bracco Imaging S.p.A Process for the preparation of chelated compounds
GB201421161D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Also Published As

Publication number Publication date
EP3223862A1 (en) 2017-10-04
RU2017116217A (ru) 2018-12-28
RU2017116217A3 (es) 2019-06-04
CA2967873C (en) 2023-04-04
KR20170086048A (ko) 2017-07-25
RU2710360C2 (ru) 2019-12-26
US11186553B2 (en) 2021-11-30
MX381348B (es) 2025-03-12
CN118141955A (zh) 2024-06-07
GB201421161D0 (en) 2015-01-14
CA2967873A1 (en) 2016-06-02
JP6709216B2 (ja) 2020-06-10
BR112017010867B1 (pt) 2024-01-02
CN106999614A (zh) 2017-08-01
AU2015352418B2 (en) 2021-05-27
BR112017010867A2 (pt) 2018-01-09
US20170266304A1 (en) 2017-09-21
KR102456908B1 (ko) 2022-10-21
AU2015352418A1 (en) 2017-05-18
JP2017538685A (ja) 2017-12-28
WO2016083597A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
MX2017006799A (es) Formulaciones de complejo de metal.
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
PT3303307T (pt) Novos compostos de quelato de gadolínio para utilização em imagiologia por ressonância magnética
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201692219A1 (ru) Способы получения противовирусных соединений
AR097158A1 (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
EP2831069A4 (en) ISOXAZOL-beta-lactamase INHIBITORS
CR20150589A (es) Compuestos de biheteroarilo y usos de los mismos
DK3386991T3 (da) Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase
DK3233843T3 (da) Isoxazol-hydraxamsyreforbindelser som LPXC-hæmmere
GT201300254A (es) Triazolopiridinas
DK3687996T3 (da) Salte af pyrrolotriazinderivater anvendelige som tam-inhibitorer
AR102790A1 (es) Composiciones antimicrobianas y métodos relacionados para tratar productos alimenticios y superficies
DK3544981T3 (da) Benzodiazoliumforbindelser som enac-inhibitorer
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
IL264506B (en) History of oxadiazolopyridine for use as gellin o-acyl transferase inhibitors
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
MX387796B (es) Compuestos de aminocarbonilcarbamato.
MX379017B (es) Formulaciones de complejo de lantanido.
CL2018001067A1 (es) Compuesto piranodipiridínico.
BR112017026807A2 (pt) agentes solubilizantes para compostos ativos funcionais
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana